Symbols / IBIO
IBIO Chart
About
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and MUC16 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells; and TROP-2 x CD3 bispecific antibody that is developed with EngageTx platform to harness T cells to kill TROP-2–expressing tumors while minimizing the cytokine release that often limits the tolerability of T-cell engagers. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. The company was formerly known as iBioPharma, Inc. and changed its name to iBio, Inc. in August 2009. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 79.10M |
| Enterprise Value | 28.86M | Income | -24.74M | Sales | 300.00K |
| Book/sh | 1.88 | Cash/sh | 1.53 | Dividend Yield | — |
| Payout | 0.00% | Employees | 20 | IPO | — |
| P/E | — | Forward P/E | -7.70 | PEG | — |
| P/S | 263.68 | P/B | 1.22 | P/C | — |
| EV/EBITDA | -1.17 | EV/Sales | 96.19 | Quick Ratio | 8.93 |
| Current Ratio | 9.04 | Debt/Eq | 4.33 | LT Debt/Eq | — |
| EPS (ttm) | -1.00 | EPS next Y | -0.30 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-02-10 16:00 | ROA | -36.99% |
| ROE | -70.22% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -84.91% | Profit Margin | 0.00% | Shs Outstand | 34.54M |
| Shs Float | 25.06M | Short Float | 11.93% | Short Ratio | 1.37 |
| Short Interest | — | 52W High | 6.89 | 52W Low | 0.56 |
| Beta | 1.25 | Avg Volume | 5.87M | Volume | 586.94K |
| Target Price | $5.25 | Recom | Strong_buy | Prev Close | $2.22 |
| Price | $2.29 | Change | 3.15% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$5.25
Mean price target
2. Current target
$2.29
Latest analyst target
3. DCF / Fair value
$-5.91
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.29
Low
$5.00
High
$6.00
Mean
$5.25
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-12 | main | Chardan Capital | Buy → Buy | $5 |
| 2025-10-21 | init | Oppenheimer | — → Outperform | $5 |
| 2025-10-17 | init | Leerink Partners | — → Outperform | $2 |
| 2025-06-25 | main | Chardan Capital | Buy → Buy | $5 |
| 2025-05-06 | main | Chardan Capital | Buy → Buy | $5 |
| 2025-05-05 | main | Chardan Capital | Buy → Buy | $5 |
| 2024-12-17 | init | LUCID CAPITAL MARKETS | — → Buy | $6 |
| 2024-07-22 | init | Brookline Capital | — → Buy | $4 |
| 2024-06-03 | main | Chardan Capital | Buy → Buy | $5 |
| 2024-05-28 | init | Chardan Capital | — → Buy | $5 |
- iBio (NASDAQ:IBIO) Rating Lowered to Sell at Wall Street Zen - MarketBeat Sat, 14 Feb 2026 07
- IBIO: Chardan Capital Maintains 'Buy' Rating with Steady Price T - GuruFocus hu, 12 Feb 2026 14
- iBio, Inc. (IBIO) Reports Q1 Loss - Yahoo Finance Wed, 12 Nov 2025 08
- iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update - GlobeNewswire Wed, 12 Nov 2025 08
- iBio (NASDAQ: IBIO) to Discuss Obesity Pipeline at 8th Evercore Healthcare Conference - Stock Titan Mon, 24 Nov 2025 08
- Oppenheimer initiates iBio stock with Outperform rating on obesity drug potential - Investing.com Mon, 20 Oct 2025 07
- iBio, Inc. (IBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Nasdaq Mon, 02 Feb 2026 08
- Why is Biotech Stock iBio Up over 50%? - TipRanks ue, 09 Dec 2025 08
- iBio's (IBIO) Buy Rating Reiterated at Chardan Capital - MarketBeat hu, 12 Feb 2026 13
- iBio Insiders Placed Bullish Bets Worth US$655.0k - Yahoo Finance Sat, 20 Dec 2025 08
- iBio (NASDAQ: IBIO) to share new IBIO-610 preclinical data at ObesityWeek and PEGS Europe - Stock Titan ue, 21 Oct 2025 07
- iBio stock price target lowered to $1.60 by Brookline Capital Markets - Investing.com Wed, 27 Aug 2025 07
- iBio (NASDAQ: IBIO) fireside chat Nov 10 at 8:30 a.m. ET on obesity pipeline, Guggenheim - Stock Titan hu, 23 Oct 2025 07
- iBio Announces Pricing of $50 Million Public Offering - Yahoo Finance ue, 19 Aug 2025 07
- Ibio stock soars after securing $26M in private placement financing - Investing.com Fri, 09 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 18382 | 49999 | — | Purchase at price 2.72 per share. | ARKOWITZ DAVID A. | Director | — | 2025-01-10 00:00:00 | D |
| 1 | 1838 | 4999 | — | Purchase at price 2.72 per share. | CLARK WILLIAM D | Director | — | 2025-01-10 00:00:00 | D |
| 2 | 9191 | 25000 | — | Purchase at price 2.72 per share. | SENDER GARY L. | Director | — | 2025-01-10 00:00:00 | D |
| 3 | 9191 | 25000 | — | Purchase at price 2.72 per share. | BRENNER MARTIN | Chief Executive Officer | — | 2025-01-10 00:00:00 | D |
| 4 | 9191 | 25000 | — | Purchase at price 2.72 per share. | DURAN FELIPE | Chief Financial Officer | — | 2025-01-10 00:00:00 | D |
| 5 | 9191 | 25000 | — | Purchase at price 2.72 per share. | BANJAK MARC | Officer | — | 2025-01-10 00:00:00 | D |
| 6 | 183823 | 499999 | — | Purchase at price 2.72 per share. | PARADA ANTONIO BERNARDINO GUIMARAES | Director | — | 2025-01-10 00:00:00 | I |
Financials
| Line Item | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -17.04M | -15.02M | -27.75M | -25.72M |
| TotalUnusualItems | 0.00 | 1.00M | -98.00K | 607.00K |
| TotalUnusualItemsExcludingGoodwill | 0.00 | 1.00M | -98.00K | 607.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -18.38M | -15.44M | -29.31M | -29.51M |
| ReconciledDepreciation | 1.13M | 1.25M | 1.38M | 3.79M |
| ReconciledCostOfRevenue | 216.00K | 1.46M | ||
| EBITDA | -17.04M | -14.02M | -27.85M | -25.72M |
| EBIT | -18.16M | -15.27M | -29.23M | -29.51M |
| NetInterestIncome | 225.00K | 191.00K | 130.00K | 177.00K |
| InterestExpense | 212.00K | 172.00K | 83.00K | 0.00 |
| InterestIncome | 437.00K | 363.00K | 213.00K | 177.00K |
| NormalizedIncome | -18.38M | -16.44M | -29.21M | -29.51M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -18.38M | -24.91M | -65.01M | -50.30M |
| TotalExpenses | 19.00M | 16.86M | 29.34M | 31.58M |
| TotalOperatingIncomeAsReported | -18.60M | -16.63M | -29.34M | -29.70M |
| DilutedAverageShares | 10.50M | 3.83M | 612.00K | 436.05K |
| BasicAverageShares | 10.50M | 3.83M | 612.00K | 436.05K |
| DilutedEPS | -1.75 | -6.50 | -106.19 | -115.60 |
| BasicEPS | -1.75 | -6.50 | -106.19 | -115.60 |
| DilutedNIAvailtoComStockholders | -18.38M | -24.91M | -65.01M | -50.39M |
| NetIncomeCommonStockholders | -18.38M | -24.91M | -65.01M | -50.39M |
| PreferredStockDividends | 88.00K | 260.00K | ||
| NetIncome | -18.38M | -24.91M | -65.01M | -50.39M |
| MinorityInterests | 0.00 | 1.00K | 6.00K | |
| NetIncomeIncludingNoncontrollingInterests | -18.38M | -24.91M | -65.01M | -50.39M |
| NetIncomeFromTaxLossCarryforward | 0.00 | -88.00K | ||
| NetIncomeDiscontinuousOperations | 0.00 | -9.46M | -35.70M | -20.79M |
| NetIncomeContinuousOperations | -18.38M | -15.44M | -29.31M | -29.51M |
| PretaxIncome | -18.38M | -15.44M | -29.31M | -29.51M |
| OtherIncomeExpense | 1.00M | -98.00K | 7.00K | 10.21M |
| OtherNonOperatingIncomeExpenses | 7.00K | 12.00K | ||
| SpecialIncomeCharges | 0.00 | 1.00M | 0.00 | 607.00K |
| GainOnSaleOfPPE | 0.00 | 1.00M | 0.00 | |
| OtherSpecialCharges | -607.00K | -10.20M | ||
| GainOnSaleOfSecurity | -98.00K | |||
| NetNonOperatingInterestIncomeExpense | 225.00K | 191.00K | 130.00K | 177.00K |
| InterestExpenseNonOperating | 212.00K | 172.00K | 83.00K | 0.00 |
| InterestIncomeNonOperating | 437.00K | 363.00K | 213.00K | 177.00K |
| OperatingIncome | -18.60M | -16.63M | -29.34M | -29.70M |
| OperatingExpense | 19.00M | 16.86M | 29.34M | 31.58M |
| ResearchAndDevelopment | 8.31M | 5.18M | 10.33M | 9.83M |
| SellingGeneralAndAdministration | 10.69M | 11.67M | 19.02M | 21.75M |
| GeneralAndAdministrativeExpense | 10.69M | 11.67M | 19.02M | 21.75M |
| OtherGandA | 10.69M | 11.67M | 19.02M | 21.75M |
| GrossProfit | 2.17M | 909.00K | ||
| CostOfRevenue | 216.00K | 1.46M | ||
| TotalRevenue | 400.00K | 225.00K | 0.00 | 1.88M |
| OperatingRevenue | 400.00K | 225.00K | 0.00 | 1.88M |
| Line Item | 2024-06-30 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 19.35M | 8.62M | 1.02M | 436.36K |
| ShareIssued | 19.35M | 8.62M | 1.02M | 436.36K |
| NetDebt | 8.64M | |||
| TotalDebt | 3.51M | 4.46M | 17.07M | 25.77M |
| TangibleBookValue | 8.03M | 15.96M | 9.99M | 58.63M |
| InvestedCapital | 15.65M | 22.31M | 28.32M | 85.65M |
| WorkingCapital | 3.62M | 11.83M | 4.15M | 14.63M |
| NetTangibleAssets | 8.03M | 15.96M | 9.99M | 58.63M |
| CapitalLeaseObligations | 2.74M | 3.48M | 4.14M | 3.60M |
| CommonStockEquity | 14.88M | 21.32M | 15.38M | 63.48M |
| TotalCapitalization | 14.88M | 22.09M | 15.38M | 63.48M |
| TotalEquityGrossMinorityInterest | 14.88M | 21.32M | 15.38M | 63.48M |
| MinorityInterest | 0.00 | -17.00K | ||
| StockholdersEquity | 14.88M | 21.32M | 15.38M | 63.48M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | -213.00K | -63.00K | |
| OtherEquityAdjustments | -213.00K | -63.00K | ||
| RetainedEarnings | -332.22M | -313.85M | -288.94M | -223.93M |
| AdditionalPaidInCapital | 347.08M | 335.16M | 304.32M | 287.62M |
| CapitalStock | 19.00K | 9.00K | 1.00K | 9.00K |
| CommonStock | 19.00K | 9.00K | 1.00K | 9.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 8.30M | 7.41M | 25.83M | 35.92M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 2.20M | 3.57M | 3.72M | 5.49M |
| LiabilitiesHeldforSaleNonCurrent | 0.00 | 1.97M | ||
| NonCurrentAccruedExpenses | 527.00K | 0.00 | ||
| TradeandOtherPayablesNonCurrent | 0.00 | 63.00K | 241.00K | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 2.20M | 3.51M | 3.48M | 3.51M |
| LongTermCapitalLeaseObligation | 2.20M | 2.74M | 3.48M | 3.51M |
| LongTermDebt | 766.00K | |||
| CurrentLiabilities | 6.11M | 3.84M | 22.11M | 30.44M |
| OtherCurrentLiabilities | 1.94M | 56.00K | ||
| CurrentDeferredLiabilities | 1.20M | 200.00K | 0.00 | 100.00K |
| CurrentDeferredRevenue | 1.20M | 200.00K | 0.00 | 100.00K |
| CurrentDebtAndCapitalLeaseObligation | 1.31M | 953.00K | 13.60M | 22.25M |
| CurrentCapitalLeaseObligation | 543.00K | 735.00K | 661.00K | 91.00K |
| CurrentDebt | 766.00K | 218.00K | 12.94M | 22.16M |
| OtherCurrentBorrowings | 766.00K | 218.00K | 600.00K | |
| CurrentNotesPayable | 0.00 | 12.94M | 22.16M | 0.00 |
| PensionandOtherPostRetirementBenefitPlansCurrent | 876.00K | 1.57M | 3.88M | |
| PayablesAndAccruedExpenses | 2.72M | 1.12M | 2.69M | 8.03M |
| CurrentAccruedExpenses | 469.00K | 460.00K | 414.00K | 3.48M |
| InterestPayable | 0.00 | 183.00K | 59.00K | 406.00K |
| Payables | 2.25M | 659.00K | 2.28M | 4.55M |
| OtherPayable | 64.00K | 301.00K | 160.00K | |
| TotalTaxPayable | 0.00 | 268.00K | 284.00K | 295.00K |
| AccountsPayable | 2.19M | 358.00K | 1.85M | 4.26M |
| TotalAssets | 23.18M | 28.73M | 41.21M | 99.41M |
| TotalNonCurrentAssets | 13.46M | 13.06M | 14.95M | 54.34M |
| OtherNonCurrentAssets | 210.00K | 215.00K | 253.00K | 43.31M |
| NonCurrentPrepaidAssets | 26.00K | 26.00K | 50.00K | 103.00K |
| NonCurrentNoteReceivables | 1.10M | 1.08M | 1.71M | 1.63M |
| NonCurrentAccountsReceivable | 5.10M | |||
| GoodwillAndOtherIntangibleAssets | 6.85M | 5.37M | 5.39M | 4.85M |
| OtherIntangibleAssets | 6.85M | 5.37M | 5.39M | 4.85M |
| NetPPE | 5.28M | 6.37M | 7.55M | 4.44M |
| AccumulatedDepreciation | -2.24M | -1.49M | -604.00K | 0.00 |
| GrossPPE | 7.52M | 7.86M | 8.15M | 4.44M |
| ConstructionInProgress | 0.00 | 1.37M | 3.37M | |
| OtherProperties | 2.87M | 3.21M | 3.54M | 3.07M |
| MachineryFurnitureEquipment | 3.96M | 3.95M | 3.92M | 0.00 |
| BuildingsAndImprovements | 695.00K | 695.00K | 695.00K | 0.00 |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 9.72M | 15.67M | 26.26M | 45.07M |
| OtherCurrentAssets | 1.03M | 749.00K | 664.00K | 1.55M |
| AssetsHeldForSaleCurrent | 0.00 | 18.07M | 3.90M | |
| RestrictedCash | 0.00 | 3.02M | 0.00 | |
| PrepaidAssets | 1.55M | 2.07M | ||
| Inventory | 3.90M | 27.00K | ||
| WorkInProcess | 4.00K | 27.00K | ||
| RawMaterials | 3.90M | 0.00 | ||
| Receivables | 105.00K | 713.00K | 204.00K | 6.10M |
| OtherReceivables | 105.00K | 204.00K | 5.10M | 5.10M |
| NotesReceivable | 0.00 | 713.00K | 0.00 | |
| AccountsReceivable | 0.00 | 1.00M | 426.00K | |
| CashCashEquivalentsAndShortTermInvestments | 8.58M | 14.21M | 4.30M | 33.52M |
| OtherShortTermInvestments | 0.00 | 10.85M | 19.57M | |
| CashAndCashEquivalents | 8.58M | 14.21M | 4.30M | 22.68M |
| Line Item | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| FreeCashFlow | -15.32M | -18.76M | -36.17M | -49.11M |
| RepurchaseOfCapitalStock | 0.00 | -7.00K | -39.00K | 0.00 |
| RepaymentOfDebt | -695.00K | -2.03M | -9.62M | -5.83M |
| IssuanceOfDebt | 0.00 | 895.00K | 500.00K | 0.00 |
| IssuanceOfCapitalStock | 3.54M | 25.52M | 11.49M | 0.00 |
| CapitalExpenditure | -16.00K | -210.00K | -5.74M | -11.63M |
| InterestPaidSupplementalData | 212.00K | 749.00K | 687.00K | 1.04M |
| EndCashPosition | 8.79M | 14.43M | 7.58M | 28.67M |
| BeginningCashPosition | 14.43M | 7.58M | 28.67M | 77.40M |
| EffectOfExchangeRateChanges | 0.00 | 33.00K | 0.00 | -1.00K |
| ChangesInCash | -5.63M | 6.85M | -21.13M | -48.73M |
| FinancingCashFlow | 8.93M | 24.49M | 2.30M | -6.12M |
| CashFlowFromContinuingFinancingActivities | 8.93M | 24.49M | 2.30M | -6.12M |
| NetOtherFinancingCharges | -294.00K | 116.00K | -22.00K | -372.00K |
| ProceedsFromStockOptionExercised | 6.38M | 0.00 | 0.00 | 77.00K |
| NetPreferredStockIssuance | 0.00 | 78.28M | ||
| PreferredStockIssuance | 0.00 | 78.28M | ||
| NetCommonStockIssuance | 3.54M | 25.52M | 11.45M | 0.00 |
| CommonStockPayments | 0.00 | -7.00K | -39.00K | 0.00 |
| CommonStockIssuance | 3.54M | 25.52M | 11.49M | 0.00 |
| NetIssuancePaymentsOfDebt | -695.00K | -1.14M | -9.12M | -5.83M |
| NetShortTermDebtIssuance | 0.00 | -1.51M | -9.32M | 0.00 |
| ShortTermDebtPayments | 0.00 | -1.51M | -9.32M | 0.00 |
| NetLongTermDebtIssuance | -695.00K | 375.00K | 193.00K | -5.83M |
| LongTermDebtPayments | -695.00K | -520.00K | -307.00K | -5.83M |
| LongTermDebtIssuance | 0.00 | 895.00K | 500.00K | 0.00 |
| InvestingCashFlow | 742.00K | 906.00K | 7.01M | -5.13M |
| CashFlowFromContinuingInvestingActivities | 742.00K | 906.00K | 7.01M | -5.13M |
| NetOtherInvestingChanges | -1.50M | |||
| InterestReceivedCFI | 758.00K | 0.00 | ||
| NetInvestmentPurchaseAndSale | 0.00 | 10.84M | 6.50M | -19.82M |
| SaleOfInvestment | 0.00 | 10.84M | 13.62M | 4.00M |
| PurchaseOfInvestment | 0.00 | -7.12M | -23.82M | |
| NetBusinessPurchaseAndSale | 0.00 | -692.00K | 0.00 | |
| PurchaseOfBusiness | 0.00 | -692.00K | 0.00 | |
| NetIntangiblesPurchaseAndSale | 0.00 | 1.00M | 0.00 | -4.30M |
| SaleOfIntangibles | 0.00 | 1.00M | 0.00 | |
| PurchaseOfIntangibles | 0.00 | -4.30M | -242.00K | |
| NetPPEPurchaseAndSale | -16.00K | -94.00K | -3.14M | -7.33M |
| SaleOfPPE | 0.00 | 116.00K | 2.60M | 0.00 |
| PurchaseOfPPE | -16.00K | -210.00K | -5.74M | -7.33M |
| OperatingCashFlow | -15.30M | -18.55M | -30.44M | -37.48M |
| CashFlowFromContinuingOperatingActivities | -15.30M | -18.55M | -30.44M | -37.48M |
| ChangeInWorkingCapital | 479.00K | -3.17M | 5.87M | 3.24M |
| ChangeInOtherWorkingCapital | 250.00K | 200.00K | -100.00K | 7.00K |
| ChangeInOtherCurrentLiabilities | -436.00K | -389.00K | -101.00K | -15.00K |
| ChangeInPayablesAndAccruedExpense | 1.07M | -3.22M | 47.00K | 2.68M |
| ChangeInAccruedExpense | -758.00K | -1.73M | 672.00K | 1.44M |
| ChangeInPayable | 1.83M | -1.49M | -625.00K | 1.24M |
| ChangeInAccountPayable | 1.83M | -1.49M | -625.00K | 1.24M |
| ChangeInPrepaidAssets | -408.00K | 238.00K | 938.00K | 228.00K |
| ChangeInInventory | 0.00 | -1.01M | -3.87M | 772.00K |
| ChangeInReceivables | 0.00 | 6.10M | 4.21M | -10.74M |
| ChangesInAccountReceivables | 0.00 | 1.00M | -886.00K | -426.00K |
| OtherNonCashItems | -62.00K | 32.00K | 167.00K | -52.00K |
| StockBasedCompensation | 1.53M | 2.04M | 4.39M | 4.38M |
| ProvisionandWriteOffofAssets | 0.00 | 4.92M | 0.00 | |
| AssetImpairmentCharge | 0.00 | 3.10M | 18.46M | 1.76M |
| AmortizationOfSecurities | 0.00 | 67.00K | 312.00K | 216.00K |
| DepreciationAmortizationDepletion | 1.13M | 1.25M | 1.38M | 3.79M |
| DepreciationAndAmortization | 1.13M | 1.25M | 1.38M | 3.79M |
| AmortizationCashFlow | 20.00K | 20.00K | 126.00K | 401.00K |
| AmortizationOfIntangibles | 20.00K | 20.00K | 126.00K | 401.00K |
| Depreciation | 1.11M | 1.23M | 1.25M | 3.39M |
| OperatingGainsLosses | 3.10M | -680.00K | -607.00K | 143.00K |
| GainLossOnInvestmentSecurities | 98.00K | |||
| GainLossOnSaleOfPPE | 0.00 | 3.91M | -773.00K | 0.00 |
| NetIncomeFromContinuingOperations | -18.38M | -24.91M | -65.01M | -50.30M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for IBIO
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|